Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial

BMJ (Online)

Volumn 341, Issue 7766, 2010, Pages 239-

  Dillner, Joakim ^a,b   Kjaer, Susanne K ^c   Wheeler, Cosette M ^d   Sigurdsson, Kristján ^e   Iversen, Ole Erik ^f   Hernandez Avila, Mauricio ^g   Perez, Gonzalo ^h   Brown, Darron R ⁱ   Koutsky, Laura A ^j   Tay, Eng Hseon ^k   García, Patricia ^l   Ault, Kevin A ^m   Garland, Suzanne M ⁿ   Leodolter, Sepp ^o   Olsson, Sven Eric ^p   Tang, Grace W K ^q   Ferris, Daron G ^r   Paavonen, Jorma ^s   Lehtinen, Matti ^t   Steben, Marc ^u   Bosch, F Xavier ^v   Joura, Elmar A ^o   Majewski, Slawomir ^w   Muñoz, Nubia ^x   Myers, Evan R ^y   Villa, Luisa L ^z   Taddeo, Frank J ^aa   Roberts, Christine ^aa   Tadesse, Amha ^aa   Bryan, Janine T ^aa   Maansson, Roger ^aa   Lu, Shuang ^aa   Vuocolo, Scott ^aa   Hesley, Teresa M ^aa   Barr, Eliav ^aa   Haupt, Richard ^aa   more..

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e National Cancer Detection Clinic   (Iceland)

^f UNIVERSITY OF BERGEN   (Norway)

^g INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^h UNIVERSIDAD DEL ROSARIO   (Colombia)

ⁱ INDIANA UNIVERSITY   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^l UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^m EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF MELBOURNE   (Australia)

^o MEDICAL UNIVERSITY OF VIENNA   (Austria)

^p DANDERYD HOSPITAL   (Sweden)

^q UNIVERSITY OF HONG KONG   (Hong Kong)

^r MEDICAL COLLEGE OF GEORGIA   (United States)

^s HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^t UNIVERSITY OF TAMPERE   (Finland)

^u INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^v BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^w MEDICAL UNIVERSITY OF WARSAW   (Poland)

^x Instituto Nacional de Cancerología   (Colombia)

^y DUKE UNIVERSITY MEDICAL CENTER   (United States)

^z LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^aa MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; CANCER VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; LIFESPAN; MAJOR CLINICAL STUDY; POPULATION; PREGNANCY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SEXUALITY; UNIVERSITY HOSPITAL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VAGINAL INTRAEPITHELIAL NEOPLASIA; VULVA CARCINOMA; CARCINOMA IN SITU; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; TREATMENT OUTCOME; UROGENITAL TRACT TUMOR; UTERINE CERVIX TUMOR; VAGINA TUMOR; VULVA TUMOR;

ADOLESCENT; ADULT; CANCER VACCINES; CARCINOMA IN SITU; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONDYLOMATA ACUMINATA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; UROGENITAL NEOPLASMS; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS; VULVAR NEOPLASMS; YOUNG ADULT;

EID: 77955099933     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c3493     Document Type: Article

References (28)

1. Ferlay J, Bray F, Pisani P, ParkinDM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No 5, version 2.0. IARCPress, 2004
2. World Health Organization. Human papillomavirus infection and cervical cancer. 2004. www.who.int/vaccine-research/diseases/hpv/en/.
3. Clarke P, Ebel C, CatottiDN, Stewart S. The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 1996;7:197-200. (Pubitemid 26191688)
4. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998;9:571-8. (Pubitemid 28474812)
5. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397-403.
6. Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004;15:501-8.
7. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician 2004;70:2335-42.
8. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005;32:S82-S90.
9. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: diagnosis, treatment and prevention. Clin Infect Dis 2002;35:S210-S224. (Pubitemid 35178333)
10. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64. (Pubitemid 40656461)
11. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005;191:1796-807.
12. Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 2006;30:1513-8. (Pubitemid 44808787)
13. Von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-604.
14. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009;199:805-14.
15. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsaguë X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27. (Pubitemid 36159887)
16. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8.
17. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 2007;369:1693-702.
18. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
19. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
20. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
21. Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med 2005;50:807-10.
22. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. Theory Meth 1998;27:1305-22.
23. The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virologic evidence of HPV infection. J Infect Dis 2007;196:1438-46.
24. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004;191:114-20.
25. Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007;196:1447-54. (Pubitemid 351411979)
26. Bergeron C, Breugelmans JG, Bouee S, Lorans C, Benard S, Remy V. [Cervical cancer screening and associated treatment costs in France.] Gynecol Obstet Fertil 2006;34:1036-42.
27. Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 2004;55:319-31.
28. Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995;33:2058-63.